Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid-19 entities : Relief therapeutics holding sa save search
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk
Published: 2022-07-04 (Crawled : 10:00) - biospace.com/
RLFTF | $1.43 3.8K
|
n/a
| Email alert
Add to watchlist
RLFTY | $1.4006 733.33% 100
|
n/a
| Email alert
Add to watchlist
NRXP 1 d | $3.005 -0.5% 170K
|
Manufacturing
| Email alert
Add to watchlist
covid-19 fda risk collaboration aviptadil authorization emergency use authorization
Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U.S. National Institutes of Health (NIH) Study of Intravenous Aviptadil in Critical COVID-19 Patients
Published: 2022-05-31 (Crawled : 08:00) - biospace.com/
RLFTF | $1.43 3.8K
|
n/a
|
| O: 0.25%
H: 12.5%
C: 9.0%
RLFTY | $1.4006 733.33% 100
|
n/a
|
| O: 6.56%
H: 3.85%
C: 3.85%
covid-19 aviptadil health
Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19
Published: 2022-05-26 (Crawled : 12:00) - biospace.com/
RLFTF | $1.43 3.8K
|
n/a
|
| O: -9.48%
H: 4.19%
C: -39.05%
RLFTY | $1.4006 733.33% 100
|
n/a
|
| O: -40.54%
H: 20.91%
C: -15.45%
NRXP 1 d | $3.005 -0.5% 170K
|
Manufacturing
|
| O: -38.37%
H: 1.11%
C: -32.16%
covid-19 collaboration aviptadil health
Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19
Published: 2022-04-01 (Crawled : 08:00) - biospace.com/
RLFTF | $1.43 3.8K
|
n/a
|
| O: -9.87%
H: 10.63%
C: 10.63%
NRXP 1 d | $3.005 -0.5% 170K
|
Manufacturing
|
| O: 0.82%
H: 0.77%
C: -2.02%
covid-19 covid collaboration aviptadil trial
Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment
Published: 2022-02-16 (Crawled : 09:00) - biospace.com/
RLFTF | $1.43 3.8K
|
n/a
|
| O: -7.15%
H: 7.7%
C: 6.89%
covid-19 aviptadil health covid report collaboration enroll
Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who've Exhausted All Approved Therapies
Published: 2022-01-19 (Crawled : 10:00) - biospace.com/
RLFTF | $1.43 3.8K
|
n/a
|
| O: 1.51%
H: 3.09%
C: -1.37%
RLFTY | $1.4006 733.33% 100
|
n/a
|
| O: -6.53%
H: 3.29%
C: 3.29%
covid-19 aviptadil expansion program respiratory covid report collaboration
Relief Reports US Collab. Partner Announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
Published: 2022-01-06 (Crawled : 10:00) - biospace.com/
RLFTF | $1.43 3.8K
|
n/a
|
| O: 19.47%
H: 3.85%
C: -11.85%
RLFTY | $1.4006 733.33% 100
|
n/a
|
| O: 2.87%
H: 0.0%
C: 0.0%
NRXP 1 d | $3.005 -0.5% 170K
|
Manufacturing
|
| O: -3.39%
H: 6.19%
C: 3.92%
covid-19 treatment fda aviptadil risk covid media submission
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.